JNJ
JOHNSON & JOHNSON
Latest Form 4:Sale$4.0MbyTaubert Jennifer L (EVP, WWC. Innovative Medicine) · filed Aug 18, 2026
JOHNSON & JOHNSON (JNJ) has 29 SEC Form 4 filings (144 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 18, 2026.
The most active filer is CEO and Chairman of the Board Duato Joaquin with 3 filings. Insiders have net sold $62.3M over the trailing 6 months.
- Industry:Drug Manufacturers - General
- CEO:Joaquin Duato
- Employees:141,700
- HQ:New Brunswick, NJ, US
- IPO:1962-01-02
Insider Buying
$258K
reported purchases (SEC code P)
Insider Selling
$155.7M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$645.9B
latest known value
Earnings: last 7 quarters
| Source | ||||||
|---|---|---|---|---|---|---|
Taubert Jennifer LFirst in 12 months | EVP, WWC. Innovative Medicine | Sale | 15,000 | $4.0M | Aug 18 | SEC ↗ |
| CEO and Chairman of the Board | Sale | 123,291 | $32.2M | Aug 14 | SEC ↗ | |
Duato JoaquinFirst in 6 months | CEO and Chairman of the Board | Sale | 48,480 | $12.5M | Aug 7 | SEC ↗ |
Forminard ElizabethFirst filing | EVP, Chief Legal Officer | Sale | 15,918 | $4.1M | Aug 7 | SEC ↗ |
Broadhurst VanessaFirst in 5 months | EVP, Global Corp Affairs | Sale | 23,054 | $5.8M | Jul 21 | SEC ↗ |
Wengel Kathryn EFirst filing | EVP, Chief TO and Risk Officer | Sale | 10,000 | $2.4M | Jun 12 | SEC ↗ |
Decker Robert JFirst filing | VP Corporate Controller | Sale | 4,075 | $1.0M | Mar 3 | SEC ↗ |
| EVP, WW Chair, MedTech | Sale | 1,322 | $325K | Feb 23 | SEC ↗ | |
| Exec VP, CFO | Sale | 89,654 | $21.8M | Feb 18 | SEC ↗ | |
Swanson James D.First filing | EVP, CIO | Sale | 41,559 | $10.1M | Feb 18 | SEC ↗ |
Swanson James D.First filing | EVP, CIO | Sale | 20,521 | $5.0M | Feb 18 | SEC ↗ |
REED JOHN CFirst in 4 months | EVP, Innovative Medicine, R&D | Sale | 53,931 | $13.1M | Feb 18 | SEC ↗ |
Schmid TimothyFirst filing | EVP, WW Chair, MedTech | Sale | 22,623 | $5.5M | Feb 18 | SEC ↗ |
Broadhurst VanessaFirst filing | EVP, Global Corp Affairs | Sale | 6,197 | $1.5M | Feb 18 | SEC ↗ |
Duato JoaquinFirst filing | CEO and Chairman of the Board | Sale | 100,000 | $22.1M | Jan 28 | SEC ↗ |
MORIKIS JOHN GFirst filing | Director | Purchase | 1,250 | $258K | Dec 1 | SEC ↗ |
REED JOHN CFirst filing | EVP, Innovative Medicine, R&D | Sale | 21,721 | $4.2M | Oct 20 | SEC ↗ |
Taubert Jennifer LFirst filing | EVP, WWC. Innovative Medicine | Sale | 56,471 | $10.0M | Sep 5 | SEC ↗ |
Congress trading JNJ
See timeline →- RRep. Rich McCormickSale$1,001 - $15,0002026-07-30
- DRep. Ro KhannaPurchase$1,001 - $15,0002026-07-02
- RSen. Tommy TubervilleSale$15,001 - $50,0002024-10-29
- RRep. Thomas H. KeanSale$1,001 - $15,0002026-06-02
- RRep. Thomas H. KeanSale$1,001 - $15,0002026-06-29
- DRep. Lloyd DoggettPurchase$1,001 - $15,0002026-06-09
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
JOHNSON & JOHNSON is in the Healthcare sector.